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Abstract
Purpose Indicators based on the number of drugs in the
medication list are sometimes used to reflect quality of drug
treatment. This study aimed to evaluate the concurrent validity
of such polypharmacy indicators, i.e., their ability to differen-
tiate between appropriate and suboptimal drug treatment.
Methods In 200 hip fracture patients (≥65 years of age),
consecutively recruited to a randomized controlled study in
Sahlgrenska University Hospital in 2009, quality of drug
treatment at study entry was assessed according to a gold
standard as well as to indicators based on the number of drugs
in the medication list. As gold standard, two specialist physi-
cians independently assessed and then agreed on the quality
for each patient, after initial screening with Screening Tool of
Older Persons’ potentially inappropriate Prescriptions
(STOPP) and Screening Tool to Alert to Right Treatment
(START). Suboptimal drug treatment was defined as ≥1
STOPP/START outcomes assessed as clinically relevant at
the individual level.
Results A total of 141 (71 %) patients had suboptimal drug
treatment according to the gold standard. The corresponding
figures according to the indicators ≥5 and ≥10 drugs were 149
(75) and 49 (25 %), respectively. The sensitivity for the
indicators ≥5 and ≥10 drugs to detect suboptimal drug treat-
ment was 0.86 (95% confidence interval: 0.80; 0.92) and 0.32
(0.25; 0.40), respectively. The specificity was 0.53 (0.41;
0.65) and 0.93 (0.82; 0.97).
Conclusions The findings suggest that no polypharmacy in-
dicator could serve as a general indicator of prescribing qual-
ity; cut-offs for such indicators need to be chosen according to
purpose.
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Introduction
Drug therapy is a common and important tool in modern
health care. To improve patient health in the best way, drug
treatment needs to be optimized according to the specific
patient. However, it is well-known that suboptimal pharma-
cotherapy is common, such as treatment with inappropriate
drugs or dosages, and/or omissions of drugs which the patient
would probably benefit from [1, 2].
In order to improve quality of drug treatment, valid indica-
tors of prescribing quality are essential. Such indicators may,
for example, be used in clinical practice to identify patients
with suboptimal drug treatment for whom the treatment needs
to be reconsidered. Furthermore, decision-makers may want
to measure quality of healthcare provided. The number of
drugs in the medication list at various cut-offs has been used
as one type of indicator of prescribing quality, both in the
scientific literature [3–8] and by decision-makers [9]. Indeed,
polypharmacy is a hot topic of today as the number of drugs
per patient is increasing [10, 11], and has been associated with
death, visits to the emergency department, gastrointestinal
bleedings, and fall accidents [12]. Cut-offs frequently used
for polypharmacy indicators are five or ten, that is, five or
more drugs as well as ten or more drugs.
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However, as far as we are aware, the ability of
polypharmacy indicators to reflect the quality of drug treat-
ment has not been evaluated. In fact, although such indicators
may be easy to measure, they may also include difficulties.
For example, undertreatment may be present in patients with
many drugs, and a high number of drugs may be fully appro-
priate in some patients. Thus, evidence on the concurrent
validity is lacking, that is, information on the sensitivity (the
proportion of patients with suboptimal treatment according to
a gold standard, also identified by an indicator), the specificity
(the proportion of patients without suboptimal treatment ac-
cording to a gold standard, also identified by an indicator), and
the predictive value (the proportion of patients correctly char-
acterized by the indicator according to the gold standard).
There is no established gold standard to determine quality
of drug treatment. However, a medical assessment is the key
step, as all prescribing has to be made after consideration of
the individual patient. This may be a challenge, especially in
older people. On the one hand, as the burden of disease
increases by age, they often qualify for multiple drugs. On
the other hand, they are more sensitive to drugs and drug
combinations due to aging organ systems [13, 14]. Thus, an
approach to a gold standard for quality of drug treatment may
be to let specialist physicians assess the medication list in
relation to the patient’s medical history. To ascertain that the
assessments are made systematically, it may be useful to start
from validated and comprehensive screening tools covering
both over- and undertreatment such as the Screening Tool of
Older Persons’ potentially inappropriate Prescriptions
(STOPP) and the Screening Tool to Alert to Right Treatment
(START) [1].
The aim of this study was to investigate the concurrent
validity of indicators based on the number of drugs in the
medication list, that is, the ability of polypharmacy indicators
to reflect the quality of drug treatment. Two cut-offs were
focused upon (≥5 and ≥10 drugs).
Methods
In a cohort of 200 hip fracture patients (≥65 years of age),
consecutively recruited to a randomized controlled study in
the departments of orthopedics, geriatrics, and medicine at
Sahlgrenska University Hospital in 2009 [15], quality of drug
treatment at study entry (admission to the hospital) was
assessed according to a gold standard as well as to
polypharmacy indicators based on the number of drugs in
the medication list. The study complies with the Declaration
of Helsinki, and ethics approval was obtained from the re-
gional ethical review board in Gothenburg.
Gold standard concerning quality of drug treatment was
systematically assessed in two steps which aimed to identify
inappropriate and missing drugs. Suboptimal drug treatment
was defined as ≥1 inappropriate drugs (overtreatment) or ≥1
missing drugs (undertreatment). For a patient without
inappropriate/missing drugs, the treatment was considered
appropriate.
First, we identified potentially suboptimal drug treatment
by the use of STOPP and START, which provide 65 criteria
for potentially inappropriate drugs and 22 criteria for poten-
tially missing drugs, respectively [1]. Then, the clinical rele-
vance of identified STOPP and/or START outcomes was
assessed at the individual level. An inappropriate drug was
defined as a clinically relevant STOPP outcome. Thus, if the
expected benefit of the medication was judged to outweigh the
potential harm, such as a neuroleptic drug in a patient with
schizophrenia, the STOPP outcome was assessed as not clin-
ically relevant, i.e., not representing an inappropriate drug. A
missing drug was defined as a clinically relevant START
outcome. Thus, if there was a clinical reason not to treat the
patient with the drug, such as an adverse drug reaction or a
contraindication, the START outcome was assessed as not
clinically relevant, i.e., not representing a missing drug. In
order to keep a conservative approach to categorizing drugs as
inappropriate or missing, we chose to categorize STOPP and
START outcomes not possible to assess concerning clinical
relevance (e.g., due to missing information) as not clinically
relevant.
The assessments were independently performed by one
general practitioner (BB) and one geriatrician (AK). They were
based on (i) medical records from both hospital and primary
care, and (ii) previously collected data including information on
risk of falls, cognition, residence, and glomerular filtration rate.
The latter, estimated with the Cockcroft-Gault equation, was
dichotomized as either ≥50 or <50 ml/min to fit the STOPP and
START criteria. In a final consensus discussion, the two spe-
cialist physicians reached agreement on all STOPP/START
outcomes, and the clinical relevance of these.
Statistics
All analyses were performed with SPSS (IBM SPSS Statistics
for Windows, Version 20.0, Armonk, NY). The Mann-
Whitney and the Chi-square tests were used for comparisons
of characteristics between patients characterized according to
the polypharmacy indicators ≥5 and ≥10 drugs. We used the
Spearman rank correlation test to investigate the correlation
between the number of drugs in the medication list and the
number of inappropriate/missing drugs. Regarding concurrent
validity for polypharmacy indicators, we calculated sensitivity
and specificity as well as positive and negative predictive
value according to cut-offs of the number of drugs in the
medication list. Logistic regression was performed to obtain
odds ratios (including 95 % confidence intervals) for subop-
timal drug treatment, as well as for over- and undertreatment,
according to the polypharmacy indicators ≥5 and ≥10 drugs.
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Adjustments were made for age, sex, cognition (defined as
impaired or not), residence (defined as nursing home or not),
and multi-dose drug dispensing (a system which has been
associated with an extensive medication list and quality of
drug treatment) [3, 4, 16]. Kappa statistics was used to assess
inter-rater agreement for STOPP/START outcomes.
Results
The 200 patients studied had a mean age of 84.5 years, rang-
ing from 65 to 98 years, and 133 (67 %) were women. The
mean number of drugs in the medication list was 7.2 (standard
deviation 3.9, range 0–21). Compared with patients with <5
and <10 drugs in the medication list, patients with ≥5 and ≥10
drugs more often had multi-dose drug dispensing (Table 1).
No statistically significant differences were found regarding
age, sex, cognition, or residence.
A total of 141 (71 %) patients had suboptimal drug treatment
according to the gold standard. The corresponding figures ac-
cording to the indicators ≥5 and ≥10 drugs were 149 (75) and 49
(25 %), respectively (Table 2). For polypharmacy indicators of
≥1 to ≥10 drugs, the sensitivity ranged between 1.00 (95 %
confidence interval: 0.97; 1.00) and 0.32 (0.25; 0.40), and the
specificity between 0.14 (0.07; 0.23) and 0.93 (0.82; 0.97). The
proportion of individuals with ≥1 to ≥10 drugs confirmed to
have suboptimal drug treatment ranged from 73 to 92 % (pos-
itive predictive value), whereas 0 to 68 % had suboptimal drug
treatment without being identified by these indicators.
The adjusted odds for suboptimal drug treatment were 4.63
times greater in patients with ≥5 drugs in the medication list
(95 % confidence interval: 2.21; 9.68). The adjusted odds for
over- and undertreatment were 5.98 (2.74; 13.0) and 1.51
(0.70; 3.29), respectively. The corresponding figures for pa-
tients with ≥10 drugs in the medication list were 5.05 (1.66;
15.4), 3.39 (1.48; 7.75), and 1.29 (0.64; 2.58).
In all, 217 inappropriate and 81 missing drugs were iden-
tified, the most frequent ones described in Table 3. The inter-
rater agreement was moderate (kappa 0.52). The number of
inappropriate/missing drugs per patient ranged from 0 to 7,
and was positively correlated to the number of drugs in the
medication list (P<0.0001; Fig. 1). The most common inap-
propriate drugs were benzodiazepines, aspirin, loop diuretics,
and neuroleptics. Missing drugs included history of cardio-
vascular disease without beta-blockers, aspirin/clopidogrel,
and statins, as well as atrial fibrillation without warfarin.
Discussion
Main study findings
Although we found a strong correlation between the number
of drugs in the medication list and suboptimal drug treatment,
it was not possible to identify a general cut-off for an indicator
of prescribing quality. Indeed, sensitivity and specificity var-
ied greatly and inversely according to the number of drugs in
the medication list. Therefore, we suggest that cut-offs for
polypharmacy indicators should be chosen by purpose as
elaborated upon below.
For an indicator of prescribing quality used in clinical
practice, a high sensitivity and a high specificity is desirable.
Indeed, if the sensitivity is too low, too many patients will be
missed for whom the drug treatment needs to be reconsidered.
If, on the other hand, the specificity is too low, resources will
be spent on activities, e.g., medication reviews, not needed.
Our results show that the sensitivity rapidly declines with
higher cut-offs for polypharmacy indicators. In fact, at a cut-
off of ≥5 drugs in the medication list, 14% of the patients with
suboptimal treatment would not be identified. By comparison,
at a cut-off of ≥10 drugs, 68 % of patients in need for drug
treatment optimization would bemissed. Correspondingly, the
specificity increases according to the number of drugs in the









Age mean±SD 84.6±6.5 84.2±8.4 84.9±6.5 84.4±7.2
median (range) 85 (65–98) 84 (65–97) 0.68 85 (65–96) 85 (65–98) 0.68
Female sex 95 (64) 38 (75) 0.16 33 (67) 100 (66) 0.89
Multi-dose drug dispensing 87 (58) 13 (25) <0.001 34 (69) 66 (44) 0.002
Impaired cognition 72 (48) 18 (35) 0.11 27 (55) 63 (42) 0.10
Residing in nursing home 47 (32) 13 (25) 0.42 19 (39) 41 (27) 0.12
Number of drugs 8.8±3.0 2.4±1.4 NA 12.2±2.5 5.5±2.6 NA
Values are presented as mean ± SD or number of patients (percentage) if not stated otherwise
NA not applicable, SD standard deviation
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medication list. Thus, using a cut-off of ≥5 or ≥10 drugs would
imply that 47 or 7 % of the patients identified, respectively,
would not have suboptimal drug treatment.
For decision-makers, on the other hand, an indicator of
prescribing quality should preferably have a high predictive
value. Indeed, trust-worthy indicators are essential for mean-
ingful benchmarking. Furthermore, as pay-for-performance is
increasingly used worldwide [17], it is important that resource
allocation procedures use validated measures. In this study,
the positive predictive value for suboptimal drug treatment






According to gold standard Sensitivity
(95 % CI)
Specificity (95 % CI)







≥1 192 141 (0.73) 0 (0) 8 (1.00) 1.00 (0.97; 1.00) 0.14 (0.07; 0.23)
≥2 189 141 (0.75) 0 (0) 11 (1.00) 1.00 (0.97; 1.00) 0.19 (0.10; 0.29)
≥3 176 136 (0.77) 5 (3.5) 19 (0.79) 0.96 (0.93; 0.99) 0.32 (0.22; 0.45)
≥4 163 129 (0.79) 12 (8.5) 25 (0.68) 0.91 (0.86; 0.95) 0.42 (0.30; 0.54)
≥5 149 121 (0.81) 20 (14) 31 (0.61) 0.86 (0.80; 0.92) 0.53 (0.41; 0.65)
≥6 137 111 (0.81) 30 (21) 33 (0.52) 0.79 (0.72; 0.86) 0.56 (0.44; 0.68)
≥7 114 96 (0.84) 45 (32) 41 (0.48) 0.68 (0.61; 0.76) 0.69 (0.57; 0.79)
≥8 84 71 (0.85) 70 (50) 46 (0.40) 0.50 (0.42; 0.60) 0.78 (0.66; 0.86)
≥9 71 61 (0.86) 80 (57) 49 (0.38) 0.43 (0.35; 0.52) 0.83 (0.71; 0.90)
≥10 49 45 (0.92) 96 (68) 55 (0.36) 0.32 (0.25; 0.40) 0.93 (0.82; 0.97)
CI confidence interval, NPV negative predictive value, PPV positive predictive value
Table 3 Description of the most frequent suboptimal drug treatment, and the prevalence at two cut-offs of number of drugs in the medication list (the







Benzodiazepines in those prone to falls I 47 (24) 42 (28) 21 (43)
Aspirin at dose >150 mg day I 23 (12) 20 (13) 7 (14)
Loop diuretic for dependent ankle oedema
only, i.e., no clinical signs of heart failure
I 20 (10) 18 (12) 5 (10)
Aspirin with no history of coronary, cerebral or
peripheral arterial symptoms or occlusive arterial event
I 13 (6.5) 11 (7.4) 4 (8.2)
Long-term long-acting benzodiazepines I 13 (6.5) 12 (8.1) 6 (12)
Neuroleptic drugs in those prone to falls I 11 (5.5) 11 (7.4) 5 (10)
Beta-blocker with chronic stable angina M 10 (5.0) 9 (6.0) 4 (8.2)
Vasodilator drugs known to cause hypotension in those
with persistent postural hypotension
I 9 (4.5) 9 (6.0) 1 (2.0)
Long-term opiates in those with recurrent falls I 9 (4.5) 9 (6.0) 2 (4.1)
Aspirin or clopidogrel with a documented history of
atherosclerotic coronary, cerebral or peripheral vascular
disease in patients with sinus rhythm
M 9 (4.5) 8 (5.4) 1 (2.0)
Statin therapy with a documented history of coronary,
cerebral or peripheral vascular disease, where the
patient’s functional status remains independent for activities
of daily living and life expectancy is >5 years
M 9 (4.5) 7 (4.7) 2 (4.1)
Prolonged use of first generation antihistamines I 7 (3.5) 7 (4.7) 4 (8.2)
Warfarin in the presence of chronic atrial fibrillation M 7 (3.5) 7 (4.7) 1 (2.0)
Oestrogens without progestogen in patients with intact uterus I 6 (3.0) 6 (4.0) 4 (8.2)
Values are presented as number of patients (percentage)
ACE angiotensin converting enzyme, I inappropriate drug, M missing drug
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ranged between 73 and 92 %. Thus, the risk of suboptimal
drug treatment was high irrespective of cut-off chosen. This
may imply that merely having drug treatment may be an
indicator of suboptimal drug treatment. Furthermore, the neg-
ative predictive values for the indicators ≥5 and ≥10 drugs in
the medication list were 61 and 36 %, respectively. Thus, 39
and 64 % of the patients with <5 and <10 drugs had quality
problems regarding their drug treatment. Taken together, our
results suggest that indicators of prescribing quality based on
the number of drugs in the medication list may not be appro-
priate for benchmarking purposes.
Strengths and limitations
In this study, we provide knowledge on the concurrent validity
of polypharmacy indicators based on different cut-offs of
number of drugs in the medication list, that is, their ability to
reflect the quality of drug treatment. As far as we are aware,
such information is lacking in the scientific literature. An
important strength of our study is the choice of gold standard
to characterize the quality of drug treatment. Indeed, our gold
standard focuses on the clinical relevance, at the individual
level, of the results of validated screening tools for potential
over- and undertreatment. Another advantage is that all as-
sessments were performed by two specialist physicians with
expertise in the relevant area. Furthermore, these assessments
were based on quite extensive data both from the original
study [15] and from hospital and primary care. However, the
assessors did not meet with or talk to the patients in person.
Such an assessment strategy could have provided an even
more accurate assessment, although it was not possible with
the present patient material. Furthermore, the inter-rater agree-
ment was moderate, illustrating the subjectivity of clinical
judgments and the advantage to involve two assessors.
The fact that we have analyzed hip fracture patients implies
both strengths and limitations. Indeed, these patients may
represent a relevant subgroup of older patients since hip
fracture is a common diagnosis in Sweden where every fourth
middle-aged woman will sustain a hip fracture during her
lifetime, and one out of three hip fracture patients is a man
[18]. Furthermore, suboptimal drug treatment is common in
this patient group [19]. However, the prevalence of subopti-
mal drug treatment, especially inappropriate drugs related to
fall risk, may differ from that found in a general population of
older people, and the results may therefore mainly be appli-
cable to hip fracture patients and frail older patients. Further-
more, a limitation of this study is that the STOPP/START
tools, which were used to systemize the specialist assess-
ments, may not capture all kinds of suboptimal drug treatment.
Relation to other studies
The number of inappropriate drugs increased by the number of
drugs in the medication list, whereas the number of missing
drugs increased at ≥2 drugs and remained relatively stable there-
after. For patients with five or more medications, similar associ-
ations have been shown [20]. Indeed, many drugs in the medi-
cation list may indicate an extensive medical history, and may
implicate difficulties to choose the optimal treatment strategy.
Suboptimal drug treatment was about five times as com-
mon for patients with an extensive medication list at both cut-
offs focused upon in the present study, ≥5 and ≥10 drugs.
Treatment with inappropriate drugs contributed most promi-
nently to these figures, whereas the confidence limits for
missing drugs crossed the line of unity. Previously,
undertreatment alone has been shown to be about five times
as common in patients with ≥5 drugs in the medication list
[21]. The divergence between these figures may be explained
by the fact that the latter study used treatment guidelines as












Inappropriate/missing Inappropriate MissingFig. 1 Mean number of
inappropriate/missing drugs
(y-axis) according to number of
drugs in the medication list
(x-axis)
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gold standard. Our approach, evaluating the clinical relevance
of validated screening tools, probably provides more conser-
vative figures concerning undertreatment.
Interestingly, when looking at frequent specific inappropriate
and missing drugs, no general pattern could be identified ac-
cording to the polypharmacy indicators ≥5 and ≥10 drugs. Thus,
inappropriate drugs were not consequently more common when
a cut-off of ≥10 was used, and missing drugs were not conse-
quently more common when a cut-off of ≥5 was used.
In conclusion, this study shows that no general
polypharmacy indicator can be used to differentiate between
appropriate and suboptimal drug treatment. For researchers
and decision-makers, we provide data which can be useful
when to consider what cut-offs to choose regarding number of
drugs in the medication list, for example to identify patients at
risk of suboptimal drug treatment. Indeed, older people seem
to have a high risk of both over- and undertreatment with
drugs no matter how many drugs they have.
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